26 October 2020>: Clinical Research
A Chinese Retrospective Multicenter Study of First-Line Chemotherapy for Advanced Pancreatic Cancer
Hanzhi Cui 12BCDEF* , Jingzhi Guan 2D* , Guochao Deng 1B , Jiajia Yuan 3B , Changjie Lou 4B , Wen Zhang 5B , Aiping Zhou 5BD , Yanqiao Zhang 4D , Jun Zhou 3D , Guanghai Dai 6ADG*DOI: 10.12659/MSM.927654
Med Sci Monit 2020; 26:e927654
Figure 2 Kaplan-Meier curve of overall survival (OS) and progression-free survival (PFS) in patients treated with the regimens. (A) OS in patients treated with nab-paclitaxel and S-1 (AS), ab-paclitaxel and gemcitabine (AG), and 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX). (B) PFS of patients treated with the AS, AG, and FOLFIRINOX.